Autolus Therapeutics (AUTL) Q2 FY26 earnings call

Autolus Therapeutics delivered a strong second quarter, driven by robust AUCATZYL sales growth and significant gross margin improvement, leading to an upward revision of full-year revenue guidance. The company is expanding its commercial footprint in the U.S. and U.K. while advancing a diverse pipeline of oncology and autoimmune programs, supported by a new strategic financing facility. Management anticipates continued momentum and key clinical data readouts in the coming periods.